TB-500
About
TB-500 is a synthetic version or active-region analog related to thymosin beta-4. Research has explored thymosin beta-4 biology in cell repair, actin regulation, angiogenesis, wound healing, muscle repair, and endothelial health. Evidence includes laboratory, animal, veterinary, and limited human research contexts.
Research Applications
- Wound healing
- Inflammation and injury recovery
- Endothelial health
- Actin regulation and cell movement
- General tissue repair and recovery
Mechanism of Action
Research literature describes TB-500 as interacting with actin-related cell movement and repair processes. It is also described as promoting angiogenesis, potentially through Notch signaling pathways. These are research mechanisms rather than established therapeutic claims.
Molecular Info
- Class
- Peptide
- Reported length
- 42 amino acids
- Related compound
- Thymosin beta-4
- Primary research areas
- Wound healing, inflammation, injury recovery, and endothelial health
Dosing Guidance
- Range
- Published and clinical discussions commonly report 2–5 mg twice weekly as a research range.
- Frequency
- Frequency varies across research contexts and is presented here as educational background only.
- Timing
- Timing is not consistently defined across the available research references.
- Cycle length
- Some research discussions cite 4–8 weeks, depending on study context.
- Notes
- These details are educational context only. Protocol values are examples and should not be treated as medical instructions.
Known Risks
- Reported effects in peptide research include injection-site pain, lightheadedness, nausea, or flu-like symptoms
Regulatory & Evidence Status
- Evidence level
- Limited clinical data; mechanisms and long-term safety profile are not fully understood.
- FDA status
- Not approved for safety or therapeutic use.
- WADA status
- Prohibited.
Protocols
Example reconstitution math only. These are educational values, not medical instructions.
Standard TB-500 Protocol
Example calculation values using a 5 mg vial, 2 mL bacteriostatic water, and a 2 mg target amount.
- Vial
- 5 mg
- Water
- 2 mL
- Target
- 2000 mcg
- Syringe
- U-100 · 100 units
These example values cover reconstitution math only; scheduling, route, and administration decisions are not included.
References
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
Expert Opinion on Biological Therapy · 2012 · Review
Reviewed thymosin beta-4 properties, regenerative biology, and clinical research applications.
DOI: 10.1517/14712598.2012.634793
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry
Journal of Chromatography A · 2012 · Analytical study
Described analytical detection of TB-500 in equine urine and plasma for doping-control research.
DOI: 10.1016/j.chroma.2012.09.043
Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse
PLOS ONE · 2010 · Preclinical study
Studied thymosin beta-4 administration in a dystrophin-deficient mouse model.
DOI: 10.1371/journal.pone.0008976
For research and educational purposes only. Not medical advice. Consult a qualified healthcare professional before using any peptide. All calculations should be independently verified.
